-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical company Astellas and Seagen recently announced, enfortumab vedotin the marketing authorization application (MAA) has been the European Medicines Management Agency (EMA) accepted.
management
Enfortumab vedotin will be reviewed in an accelerated evaluation, which means that the EMA's Committee on Medicines for Human Use (CHMP) can shorten the evaluation time.
MAA's approval is based on the global Phase III EV-301 trial, which evaluated the efficacy of enfortumab vedotin in the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-based chemotherapy and PD-1/L1 inhibitors.
The results of the trial were published in the New England Journal of Medicine, and the primary endpoint of the trial was overall survival.
diagnosis
Original source:
Original source:href="" target="_blank" rel="noopener">leave a message here